Skip Nav Destination
Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)
Cancer Res (2021) 81 (13_Supplement): CT169.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
- Jia Li Low
- Sun Min Lim
- Jii Bum Lee
- Byoung Chul Cho
- Ross A Soo
Therapeutic Advances in Medical Oncology (2023) 15: 175883592211461.
- Yasir Y. Elamin
- Jacqulyne P. Robichaux
- Brett W. Carter
- Mehmet Altan
- Hai Tran
- Don L. Gibbons
- Simon Heeke
- Frank V. Fossella
- Vincent K. Lam
- Xiuning Le
- Marcelo V. Negrao
- Monique B. Nilsson
- Anisha Patel
- R.S.K. Vijayan
- Jason B. Cross
- Jianjun Zhang
- Lauren A. Byers
- Charles Lu
- Tina Cascone
- Lei Feng
- Rajyalakshmi Luthra
- Francis A. San Lucas
- Geeta Mantha
- Mark Routbort
- George Blumenschein
- Anne S. Tsao
- John V. Heymach
Cancer Cell (2022) 40 (7): 754.
- Samy Chelabi
- Xavier Mignard
- Karen Leroy
- Isabelle Monnet
- Solenn Brosseau
- Nathalie Theou-Anton
- Marie-Ange Massiani
- Sylvie Friard
- Boris Duchemann
- Elizabeth Fabre
- Etienne Giroux-Leprieur
- Jacques Cadranel
- Marie Wislez
Cancers (2021) 13 (20): 5132.
- Matthew Z Guo
- Kristen A Marrone
- Alexander Spira
- Kristine Freeman
- Susan C Scott
Oncology & Haematology (2021) 17 (1): 42.
